中国药业2013，Vol.22Issue(5)：77-78,2.
瑞舒伐他汀用于直接经皮冠状动脉介入治疗的疗效观察
Efficacy Observation of Rosuvastain on Primary PCI
摘要
Abstract
Objective To observe clinical effects of using rosuvastatin in primary PCI. Methods Retrospective analysis 208 patients who has been received primary PCI at our hospital for acute ST elevation myocardial infarction(STEMI) ,in which 106 patients took simvas-tatin before primary PCI, and set them as conventional control group, the other 102 patients took rosuvastatin before primary PCI and set them as rosuvastatin group. Aspirin and clopidogrel were given to all the patients in these two groups before operation. While in the primary PCI operation, all of the patients received nitroglycerin injection in coronary and injected heparin in vein. Results Rosuvastatin group's patients' CK - MB peak value less than conventional control group after operation, left ventricular ejection fraction greater than conventional control group and the number of STR cases greater than conventional control group a month later, the number of cardiovascular events recurrence cases evidently less than conventional control group within 1 month. Conclusion Rosuvastatin shows positive value to the treatment of AMI, it can also improve patients' myocardial ischemia symptom effectively, and protect myocardium so that improve the patients' prognosis condition.关键词
直接经皮冠状动脉介入治疗/急性ST段抬高心肌梗死/瑞舒伐他汀Key words
primary PCI/acute ST elevation myocardial infarction/rosuvastatin分类
医药卫生引用本文复制引用
张宏,姚威,罗平..瑞舒伐他汀用于直接经皮冠状动脉介入治疗的疗效观察[J].中国药业,2013,22(5):77-78,2.
